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ABSTRACT
Cancer patients treated for venous thromboembolism with low molec-
ular weight heparin (LMWH) have a better survival rate than patients
treated with unfractionated heparin (UFH). Because fibrin-associated
angiogenesis is an important determinant in the progression and metas-
tasis of many solid tumors, the effects of heparins on in vitro angiogenesis
were investigated. Both UFH and LMWH inhibited bFGF-induced pro-
liferation of human microvascular endothelial cells (hMVECs) to the same
the extent (36–60%). VEGF165-induced proliferation was inhibited to a to
a lesser extent (19–33%). Turbidity measurements and electron micros-
copy showed that the presence of LMWH during polymerization of the
fibrin matrix led to a more transparent rigid network with thin fibrin
bundles, whereas the presence of UFH resulted in a more opaque more
porous network with thick fibrin fibers. We used a human in vitro
angiogenesis model, which consisted of hMVECs seeded on top of a fibrin
matrix, and stimulated the cells with basic fibroblast growth factor plus
tumor necrosis factor a to induce capillary-like tubular structures. The
formation of capillary-like tubular structures was retarded with matrices
polymerized in the presence of LMWH (46% inhibition compared with a
control matrix for both 1.5 and 10 units/ml LMWH), whereas matrices
polymerized in the presence of UFH facilitated tubular structure forma-
tion (72 and 36% stimulation compared with a control matrix for 1.5 and
10 units/ml UFH, respectively). Similar results were obtained for cells
stimulated with vascular endothelial growth factor plus tumor necrosis
factor a. These data demonstrate the inhibitory effect of heparins on
proliferation of hMVECs and provide a novel mechanism by which
LMWH may affect tumor progression, namely reduced ingrowth of mi-
crovascular structures in a fibrinous stroma matrix by rendering it less
permissive for invasion.
INTRODUCTION
Patients with malignant diseases are at increased risk of venous
thromboembolic complications (1). As a result, many cancer patients
are treated with antithrombotic drugs, including heparins. Intravenous
dose-adjusted UFH3 has been the standard initial treatment, but recent
randomized clinical trials have shown that s.c. fixed doses of LMWH
are as safe and effective as UFH (2–4). Cancer patients who have
been treated with LMWH for their venous thromboembolisms were
found to have a significantly improved 3-month survival compared
with UFH recipients, whereas incidences of hemorrhages and throm-
boembolic recurrences were comparable in both treatment groups (5).
Several experimental studies have reported the either stimulatory or
inhibitory effects of heparins on tumor growth and metastasis (see
Ref. 6 for review). These effects may not only reflect their anticoag-
ulant function but may involve other processes, such as angiogenesis
(7). Animal studies have shown that LMWH and UFH differentially
affect angiogenesis, but the mechanisms by which they act remain
unclear (8, 9).
Angiogenesis, the formation of new blood vessels, supports the
expansion of many solid tumors and facilitates the escape of tumor
cells and thus metastasis (10, 11). Angiogenesis is driven by MVECs,
which upon activation degrade their basement membrane, migrate into
the interstitial matrix, proliferate, and form new capillary-like tubular
structures (12). Tumors release a number of angiogenic growth fac-
tors, such as VEGFs (13), fibroblast growth factors FGFs (14), and
scatter factor (15). Induction and maintenance of angiogenesis re-
quires interaction of these growth factors with their respective recep-
tors, which then activate endothelial cells (16, 17), often in concert
with other cytokines (18). Heparan sulfates and heparins modulate the
binding of many angiogenic growth factors and, hence, may affect
endothelial cell responses (19, 20). To date, the effects of heparins on
angiogenesis have been attributed to their interaction with angiogenic
growth factors. However, other steps in the process of angiogenesis
may also be influenced, in particular the interaction of MVECs with
the matrix that they invade.
In several tumor types, fibrin is a major component of the initial
stroma (21, 22). Fibrin provides scaffolding for both invasive cancer
and endothelial cells, thereby contributing to tumor growth and neo-
vascularization (23, 24). The structural and mechanical properties of
the fibrin matrix play a regulatory role in the formation of capillary-
like tubular structures (25, 26). Modifications of the structure of the
fibrin network alter its sensitivity toward proteolytic degradation (27,
28), which affects tube formation. Heparins also affect the structure of
the fibrin clot, altering its sensitivity to plasmin degradation (29).
However, it is not known to what extent LMWH or UFH affects
angiogenesis by altering the structure of this temporary matrix.
The present study evaluates the effects of UFH and LMWH on
growth factor-induced proliferation and the formation of capillary-like
tubular structures by human MVECs (hMVECs). Both compounds
reduce proliferation of hMVECs to a rather similar degree. However,
the presence of LMWH during the polymerization of fibrin decreases
the formation of tubular endothelial structures, whereas the presence
of UFH enhances its formation. These data provide a novel mecha-
nism by which LMWH may affect tumor progression, namely, re-
duced ingrowth of microvascular structures in a fibrinous stroma
matrix by rendering it less permissive for invasion.
MATERIALS AND METHODS
Materials. Penicillin/streptomycin, L-glutamine, and medium M199 with
or without phenol red, with Earle’s Balanced Salt Solution, L-glutamine, and
HEPES were obtained from BioWhittaker (Verviers, Belgium). Trichloroace-
tic acid and trypsin 1–300 (370 USP/mg) were obtained from ICN (Costa
Mesa, CA), and heat-inactivated newborn calf serum was from Life Technol-
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ogies (Paisley, Scotland). Human serum was prepared from the pooled fresh
blood of 10–20 healthy donors, obtained from a local blood bank. Fibronectin
was a gift from Dr. J. van Mourik (Central Laboratory of the Blood Transfu-
sion Service, Amsterdam, the Netherlands). A crude preparation of endothelial
cell growth factor was prepared from bovine brain (30). Thrombin and UFH
were obtained from Leo Pharmaceutical Products (Weesp, the Netherlands),
and tissue culture plastics were from Costar (Cambridge, MA). Human fibrin-
ogen (batch X 0379-51) containing 3.2 mg of plasminogen and 5 mg of plasmin
per g of fibrinogen was purchased from Chromogenix AB (Mo¨lndal, Sweden),
and the LMWH, Reviparin, was from Knoll (Ludwigshaven, Germany).
VEGF165 was a kind gift from Dr. H. Weich, (GBF, Braunsweig, Germany),
and TNFa, containing 2.45 3 107 units/mg of protein and ,40 ng of lipopo-
lysaccharide per mg of protein, was from Dr. J. Tavernier (Biogent, Gent,
Belgium). Recombinant human bFGF was purchased from PeproTech (Rocky
Hill, NJ), and [3H]thymidine was from Amersham (Buckinghamshire, United
Kingdom).
Cell Culture. HUVECs (31) and human foreskin hMVECs were isolated,
cultured, and characterized as described previously (32, 33). Cells were cul-
tured until confluence in a 5% CO2-95% air atmosphere on fibronectin-coated
dishes in M199 supplemented with 2 mM L-glutamine, 20 mM HEPES (pH
7.3), 10% heat-inactivated human serum, 10% heat-inactivated newborn calf
serum, 150 mg/ml endothelial cell growth factor, 100 IU/ml penicillin, and 100
mg/ml streptomycin. The endothelial cells were then detached with trypsin-
EDTA and transferred to new fibronectin-coated dishes at a split ratio of 1:3.
Confluent endothelial cells were used at passages 9–11 for hMVECs and at
passage 2 for HUVECs.
Proliferation Assay. Incorporation of [3H]thymidine in DNA was deter-
mined as described previously (18).
Preparation of Fibrin Matrices. Human fibrin matrices were prepared by
the addition of 0.1 unit/ml thrombin to 300 ml of 3 mg/ml fibrinogen dialyzed
against PBS [140 mM NaCl, 13.4 mM Na2HPO4z2H2O, 138 mM
NaH2PO4z2H2O (pH 7.4)] in a 1-cm2 well of a 48-well plate. The structure of
the fibrin clot was modified by varying the pH of the mixture before poly-
merization between pH 7.0 and 7.8 with NaOH or HCl. After 24 h of
polymerization, inactivation of thrombin and adjustment of the pH of the fibrin
gels to pH 7.4 was carried out by equilibrating the gels twice for 12 h and once
for 24 h with 0.5 ml of M199 containing 10% human serum and 10% newborn
calf serum.
Fig. 1. Incorporation of [3H]thymidine in DNA of hMVECs (A and B) or HUVECs (C
and D). The inhibition of growth factor-induced proliferation was studied by the addition
of 0.5 or 10 units/ml UFH or 0.5 or 10 units/ml LMWH. Data are the means of three
independent experiments for bFGF (A and C) and for VEGF165 (B and D); bars, SE.
p, P , 0.01; p p, P , 0.05.
Fig. 2. Effect of polymerization conditions on
the structure of the formed fibrin matrix: A and B,
prior to polymerization, the pH of the buffer was
altered between pH 7.0 and 7.8 (A), or 1.5 or 10
units/ml UFH and 1.5 or 10 units/ml LMWH were
added (B). After 4 h of polymerization, the struc-
ture of the fibrin was determined by measurement
of the turbidity at 340 nm (A340). Data are ex-
pressed as the means of three independent experi-
ments; bars, SE. C-E, electron micrographs of a
fibrin network formed from purified fibrinogen af-
ter polymerization without (C) or in the presence of
UFH (D) or LMWH (E).
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The influence of heparins on the structure of the fibrin matrix was studied
by the addition of 1.5 or 10 units/ml UFH or 1.5 or 10 units/ml LMWH prior
to the polymerization. After 4 h of polymerization, the matrices were washed
with culture medium.
In a parallel experiment, the structure of fibrin fibers was monitored by
turbidity measurement with a multichannel spectrophotometer at 340 nm
(Titertek multiscan; Flows Labs, McLean, VA) and was plotted against the pH
of the polymerization buffer or against the concentration of the added heparin.
For electron microscopy examination of the fibrin network structure, fibrin-
ogen was clotted on formvar-coated 200-mesh nickel grids, which were dipped
in poly-L-lysine, by the addition of 1 unit/ml thrombin in the presence or
absence of 10 units/ml LMWH or UFH. After repeated washing with water, the
specimen was dried and stained with 2% phosphotungstic acid for 1 min, and
the fibrin network formed was analyzed in a Philips 201 electron microscope.
In Vitro Angiogenesis Model. Confluent endothelial cells were detached
with trypsin-EDTA, suspended in medium, and seeded in a confluent density
on the fibrin matrices. After 24 h, the medium was replaced with medium
containing different mediators. Every 48 h, the medium was changed and
collected, for a time period of 6 days. The formation of tubular structures of
endothelial cells by invasion into the underlying matrix was analyzed by
phase-contrast microscopy. Quantification of the length of the structures
formed was performed by a computer equipped with Optimas image analysis
software connected to a monochrome CCD camera (MX5; Ref. 18).
Antigen Measurement in Conditioned Medium. u-PA antigen was meas-
ured as described previously (18). As tagging antibodies, a mixture of two
monoclonal antibodies, UK 2.1 and UK 26.15, which recognize different
epitopes of the u-PA antigen, was used. Horseradish peroxidase-conjugated
monoclonal anti-u-PA IgG (LMW 11.1) was used as a capping antibody, and
u-PA (Ukidan; Serono, Aubonne, Switzerland) as standard.
PAI-1 antigen was determined by ELISA of the conditioned media collected
from cells grown on fibrin and stimulated with different factors in M199
supplemented with 10% human serum and 10% newborn calf serum, according
to the instructions of the manufacture (Biopool, Umea, Sweden).
Statistics. Data were expressed as mean 6 SE. Statistical significance of
differences between groups was analyzed by one-way ANOVA followed by
Bonferroni’s modified t test. Differences were considered significant at
P , 0.05.
RESULTS
Effect of Heparin on Proliferation of hMVECs and HUVECs.
Proliferation was measured as the incorporation of [3H]thymidine in
hMVECs stimulated with bFGF (2.5 ng/ml) or VEGF165 (12.5 ng/ml).
Addition of a low concentration of UFH or LMWH (0.5 units/ml of
UFH or 0.5 units/ml of LMWH) to bFGF-stimulated cells resulted in
a significant decrease of [3H]thymidine incorporation (58 6 3% and
36 6 3% inhibition, respectively, compared with control). The addi-
tion of higher concentrations of both heparin preparations resulted in
similar or even further inhibition (60 6 9% and 50 6 10% inhibition,
respectively; Fig. 1A). In addition, VEGF165-induced proliferation
was inhibited by the addition of UFH and LMWH, although to a lesser
extent (33 6 3% for 0.5 units/ml UFH and 0.5 units/ml LMWH, and
to 28 6 3% and 19 6 3% for 10 units/ml UFH and LMWH,
respectively; Fig. 1B).
Interestingly, this effect of heparin was specific for hMVECs because
UFH or LMWH did not significantly affect the proliferation of HUVECs
induced by bFGF (8 6 2% and 5 6 8% for 0.5 units/ml UFH and
LMWH, respectively, and 15 6 5% for 10 units/ml; Fig. 1C) or VEGF165
(2 6 4% and 9 6 7% for 0.5 units/ml UFH and LMWH, respectively,
and 3 6 5% and 4 6 10% for 10 units/ml, respectively; Fig. 1D).
Fibrin Matrices Polymerized in Different Conditions. Previ-
ously, it was shown that the structure of fibrin depends on the pH at
which fibrin was polymerized (26, 27, 34). Fibrin matrices polymer-
ized at pH 7.0 or lower had a high turbidity, indicative of an opaque
and more porous network, whereas those polymerized in a more basic
environment (pH 7.8) had a low absorbency, indicative of a transpar-
ent, dense, and rigid network (Fig. 2A).
The presence of UFH and LMWH during fibrin polymerization also
caused an alteration of the turbidity of the matrices formed. UFH
induced an increase in turbidity and LMWH a decrease (Fig. 2B).
Electron microscopic studies of fibrin matrices confirmed that the
fibrin network formed in the presence of UFH was composed of
thicker fibrin bundles in a more porous network, whereas bundles in
the tighter network formed in the presence of LMWH were thinner
and denser (Fig. 2, C–E).
Formation of Capillary-like Tubular Structures in Various
Fibrin Matrices. hMVECs grown on a fibrin matrix and stimulated
with the combination of bFGF and TNFa (bFGF/TNFa) or VEGF165
and TNFa (VEGF165/TNFa) invaded the underlying fibrin matrix and
formed capillary-like tubular structures (18), (compare Fig. 3, A and
B). The overall length of tubular structures was considerably higher in
more porous fibrin matrices produced at pH 7.0 than in fibrin matrices
produced at pH 7.8 in both bFGF/TNFa- and VEGF165/TNFa-stim-
ulated cells (Fig. 4).
The presence of UFH and LMWH during polymerization altered
the fibrin matrices and also affected the extent of tube formation by
hMVECs (Fig. 3). The total lengths of the tubes formed after stimu-
lation with bFGF/TNFa of the cells grown on fibrin matrices poly-
merized in the presence 1.5 units/ml and 10 units/ml UFH were
increased by 72 6 10% and 36 6 8%, respectively, compared with
Fig. 3. Effect of fibrin structure on the formation of
capillary-like tubular structures. Stimulation of endothe-
lial cells with 5 ng/ml bFGF and 1 ng/ml TNFa for 6
days induced the cells to invade the fibrin matrix and
form capillary-like tubular structures. A and C–F, phase-
contrast photomicrographs of tubular structures (A, ar-
rowheads) formed by hMVECs cultured on fibrin mat-
rices formed in the presence of 1.5 or 10 units/ml UFH
(C and D, respectively), 1.5 or 10 units/ml of LMWH (E
and F, respectively) and control matrices (A). Bar repre-
sents 300 mm. B, histological cross-section. A tubular
structure, indicated by an arrowhead, is connected as
became evident by serial sections. G, the total length of
tubular structures formed after 6 days was quantified and
expressed as percentage of the values obtained after
stimulation with bFGF/TNFa on a control fibrin matrix
(no heparin added). Data are expressed as mean of six
different experiments performed with duplicate wells;
bars, SE. p, P , 0.01. The total tube length in control
matrices (100%) was 229 6 12 mm/cm2.
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control matrices (Fig. 3 and Table 1). Similar results were obtained if
cells were stimulated with VEGF165/TNFa (Table 1). However, the
presence of similar amounts of LMWH during matrix polymerization
caused a decrease in the length of tube formation compared with
control for bFGF/TNFa-stimulated cells (Fig. 3 and Table 1) and for
VEGF165/TNFa-stimulated cells (Table 1).
When UFH or LMWH was added after polymerization of the fibrin
and seeding of the hMVECs, no significant effects on tube formation
were observed for bFGF/TNFa-stimulated cells (81 6 12% and
85 6 10% of control for 1.5 units/ml and 10 units/ml UFH, respec-
tively, and 100 6 11% and 97 6 8% for 1.5 units/ml and 10 units/ml
LMWH, respectively; n 5 7; control was 294 6 44 mm/cm2). This
indicates that the effects of UFH and LMWH were mainly the result
of their effect on the structure of the fibrin matrix.
The differences in tube formation could not be explained by an
altered u-PA activity because the secretion of u-PA and PAI-1 antigen
in all conditions was similar, as shown for bFGF/TNFa-stimulated
cells (Table 2).
DISCUSSION
The present study reveals two mechanisms by which UFH and
LMWH affect angiogenesis in vitro. UFH and LMWH inhibit the
proliferation of hMVECs induced by the angiogenic factors bFGF and
VEGF165 to a similar degree, and differently affect fibrin matrix
formation. LMWH causes the formation of more rigid fibrin matrices
that inhibit capillary-like tubular structure formation, whereas UFH
contributes to the formation of a more porous fibrin matrix and thus
facilitates angiogenesis.
Angiogenesis is required for the expansion of many solid tumors
and facilitates the metastasis of tumor cells to other organs (10).
Factors altering angiogenesis may, therefore, influence these pro-
cesses and thereby the prognosis of cancer patients. Various studies
have suggested that heparins affect the proliferation of endothelial
cells by their effects on angiogenic growth factors, in particular FGFs
and VEGFs (35, 36). Both endothelial heparan sulfates and heparins
can promote the interaction of these growth factors with their recep-
tors. One may anticipate that LMWH might inhibit angiogenesis by
competing with cellular heparan sulfates for the binding of these
growth factors (37, 38). However, no major differences between UFH
and LMWH on endothelial cell proliferation were observed. Interest-
ingly, the inhibitory effect of heparin on proliferation was relatively
strong in hMVECs, whereas it was nonsignificant in HUVECs. Be-
cause angiogenesis is driven by microvascular endothelial cells, this
effect is probably relevant for tumor neovascularization.
The migration and invasion of cells depend on their detachment from,
and the new attachment of invading cells to, their extracellular matrix.
Tumor cells induce a state of hyperpermeability in the surrounding
vasculature by the release of vascular permeability factors such as VEGF
(39). Plasma proteins, including fibrinogen, extravasate. The subse-
quently formed fibrinous exudate is a major component of the initial
tumor stroma (22, 39). This temporary matrix provides an important
provisional scaffolding for invasive cells, thereby contributing to tumor
growth and neovascularization. In vitro angiogenesis studies have re-
vealed that the formation of capillary-like tubular structures by endothe-
lial cells in a fibrin matrix depends on local and controlled matrix
degradation mediated by cell-bound urokinase and plasmin (40, 41). In
addition, the structure of fibrin itself plays an important role in endothelial
cell invasion (25, 26), and as is shown here, heparins affect fibrin matrix
formation. Differences in the fibrin network structure alter its sensitivity
toward plasmin-dependent proteolysis (42, 29) and the array of epitopes
involved in endothelial cell-matrix interaction during angiogenesis (43,
44). Heparins were present during the polymerization of the fibrin matrix,
and because heparin is known to bind to fibrinogen (45, 46) as well as
fibrin (47), it might still be present in the matrix. In our in vitro model,
Fig. 4. Effect of fibrin structure on capillary tube formation. Fibrin matrices were
polymerized at pH 7.0, pH 7.4, and pH 7.8. hMVECs on top of these fibrin matrices were
stimulated with 5 ng/ml bFGF and 1 ng/ml TNFa (bFGF/TNFa) or 40 ng/ml VEGF and
1 ng/ml TNFa (VEGF/TNFa) to form invasive capillary-like tubular structures. The total
lengths of tubular structures were quantified and expressed as percentages of the values
obtained after stimulation with bFGF/TNFa or VEGF/TNFa on a control fibrin matrix
(pH 7.4). Data are expressed as means of five different experiments performed with
duplicate wells for bFGF/TNFa and three experiments in duplicate for VEGF/TNFa;
bars, SE. The total tube length in control matrices (100%) was 229 6 12 mm/cm2 for
bFGF/TNFa and 77 6 2 mm/cm2 for VEGF/TNFa.
Table 1 Effect of UFH and LMWH on fibrin gel structure as measured by the length
of endothelial tubular structures formed in the presence of a growth factor (bFGF or
VEGF) and TNFa
Fibrin matrices were polymerized in the presence of UFH (1.5 and 10 units/ml) or
LMWH (1.5 and 10 units/ml), or without addition (control matrices). hMVECs on top of
these fibrin matrices were stimulated with 5 ng/ml bFGF and 1 ng/ml TNFa (bFGF/
TNFa) or 40 ng/ml VEGF and 1 ng/mL TNFa (VEGF/TNFa) to form invasive capillary-
like tubular structures. The total length of tubular structures was quantified and expressed
as percentage of the values obtained after stimulation of hMVEC with bFGF/TNFa or
VEGF/TNFa, respectively, on a control fibrin matrix (no heparin added). Data are
expressed as means 6 SE of five different experiments performed with duplicate wells.
The total tube length in control matrices (100%) was 229 6 12 mm/cm2 for bFGF/TNFa
and 7762 mm/cm2 for VEGF/TNFa. 1 units/ml LMWH represents 1 aXa/ml LMWH.
Addition bFGF/TNFa VEGF/TNFa
None 100 6 1 100 6 2
1.5 U/ml UFH 172 6 10a 177 6 5a
10 U/ml UFH 136 6 8 138 6 4a
1.5 U/ml LMWH 46 6 6 45 6 1a
10 U/ml LMWH 46 6 4 43 6 4a
a P , 0.01.
Table 2 Accumulation of u-PA and PAI-1 antigen in conditioned media of tube-
forming hMVECs on different fibrin matrices
Stimulation of hMVEC with 5 ng/ml bFGF and 1 ng/ml TNFa induced the cells to
invade the fibrin matrix and form capillary-like tubular structures. Every 2 days, the
supernatant media were renewed. The total concentrations of u-PA and PAI-1 antigens
secreted in the conditioned media were measured by specific ELISA and expressed as the
total amount (ng) secreted over a period of 6 days. Data are the means 6 SE of three
different experiments performed with duplicate wells.
Addition
PAI-1 antigen
(ng/105 cells/6 days)
u-PA antigen
(ng/105 cells/6 days)
None 678 6 50 21 6 0.4
1.5 U/ml UFH 694 6 57 24 6 0.1
10 U/ml UFH 685 6 34 23 6 0.3
1.5 U/ml LMWH 711 6 20 23 6 0.1
10 U/ml LMWH 682 6 20 23 6 0.4
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however, the formation of capillary-like tubular structures was not af-
fected by the addition of heparins after polymerization of the matrices.
Furthermore, the amount of heparin remaining did not affect endothelial
cell proliferation. This suggestion is strengthened by our previous obser-
vation that the formation of tubular structures does not critically depend
on endothelial proliferation (18, 41). Finally, the effects of UFH and
LMWH on hMVEC proliferation were similar, whereas their effects on
capillary-like tube formation paralleled their effects on the fibrin struc-
ture. Thus, heparins may influence angiogenesis differentially by their
different effects on the fibrin structure in the fibrinous stroma of a tumor.
These data provide a novel mechanism by which LMWH may affect
tumor progression, namely reduced ingrowth of microvascular structures
in a fibrinous stroma matrix by rendering it less permissive for invasion.
In conclusion, our data indicate that heparins not only affect the
proliferation of endothelial cells, but also affect angiogenesis by
altering the structural and mechanical properties of the fibrin network.
Whereas the structural alterations of the fibrin matrix by UFH en-
hanced the invasion of the matrix by capillary-forming endothelial
cells, LMWH reduced it. These findings may contribute to the eluci-
dation of the mechanisms by which heparins may affect cancer
progression differentially.
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